JP5401465B2 - 有機化合物 - Google Patents

有機化合物 Download PDF

Info

Publication number
JP5401465B2
JP5401465B2 JP2010535355A JP2010535355A JP5401465B2 JP 5401465 B2 JP5401465 B2 JP 5401465B2 JP 2010535355 A JP2010535355 A JP 2010535355A JP 2010535355 A JP2010535355 A JP 2010535355A JP 5401465 B2 JP5401465 B2 JP 5401465B2
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
compounds
dpp
nvp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010535355A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011504903A (ja
JP2011504903A5 (https=
Inventor
ウルリッヒ・ハシーペン
マティアス・キッテルマン
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2011504903A publication Critical patent/JP2011504903A/ja
Publication of JP2011504903A5 publication Critical patent/JP2011504903A5/ja
Application granted granted Critical
Publication of JP5401465B2 publication Critical patent/JP5401465B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41J—TYPEWRITERS; SELECTIVE PRINTING MECHANISMS, i.e. MECHANISMS PRINTING OTHERWISE THAN FROM A FORME; CORRECTION OF TYPOGRAPHICAL ERRORS
    • B41J2/00—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed
    • B41J2/005—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed characterised by bringing liquid or particles selectively into contact with a printing material
    • B41J2/01—Ink jet
    • B41J2/17—Ink jet characterised by ink handling
    • B41J2/175—Ink supply systems ; Circuit parts therefor
    • B41J2/17593—Supplying ink in a solid state

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
JP2010535355A 2007-11-30 2008-11-25 有機化合物 Expired - Fee Related JP5401465B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US484607P 2007-11-30 2007-11-30
US60/004,846 2007-11-30
PCT/EP2008/066159 WO2009068531A2 (en) 2007-11-30 2008-11-25 Organic compounds

Publications (3)

Publication Number Publication Date
JP2011504903A JP2011504903A (ja) 2011-02-17
JP2011504903A5 JP2011504903A5 (https=) 2013-10-03
JP5401465B2 true JP5401465B2 (ja) 2014-01-29

Family

ID=40679052

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010535355A Expired - Fee Related JP5401465B2 (ja) 2007-11-30 2008-11-25 有機化合物

Country Status (13)

Country Link
US (2) US8252751B2 (https=)
EP (1) EP2247602B1 (https=)
JP (1) JP5401465B2 (https=)
KR (1) KR20100092461A (https=)
CN (1) CN101918423B (https=)
AU (1) AU2008328845C1 (https=)
CA (1) CA2704493A1 (https=)
ES (1) ES2418440T3 (https=)
MX (1) MX2010005914A (https=)
PL (1) PL2247602T3 (https=)
PT (1) PT2247602E (https=)
RU (2) RU2489439C2 (https=)
WO (1) WO2009068531A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2518051A4 (en) 2009-12-22 2013-10-16 Shionogi & Co ADAMANTANAMINE DERIVATIVE
CN101798270B (zh) * 2010-02-25 2013-04-17 东华大学 一种3-氨基-1-金刚烷醇的制备方法
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
EP2604591A4 (en) 2010-08-09 2015-07-22 Shionogi & Co PROCESS FOR THE PREPARATION OF AMINOADAMANTYL CARBAMATE DERIVATIVES
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013179300A2 (en) * 2012-05-04 2013-12-05 Megafine Pharma (P) Ltd. A process for the preparation of vildagliptin and its intermediate thereof
JP5929555B2 (ja) * 2012-06-28 2016-06-08 三菱瓦斯化学株式会社 ヒドロキシアダマンタンカルボン酸化合物の製造方法
US20150297573A1 (en) 2012-10-24 2015-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING Beta-CELL SURVIVAL
CN103804267B (zh) * 2014-02-21 2016-06-08 张家港威胜生物医药有限公司 一种维达列汀的合成工艺
CN105439873A (zh) * 2014-08-20 2016-03-30 天津药物研究院 3-羟基-1-金刚烷胺的制备方法
US10426818B2 (en) 2015-03-24 2019-10-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment of diabetes
CN104744334A (zh) * 2015-03-25 2015-07-01 合肥创新医药技术有限公司 维格列汀的制备方法
CN107311907A (zh) * 2017-07-29 2017-11-03 合肥创新医药技术有限公司 一种维格列汀异构体杂质的制备方法
CN111138334A (zh) * 2020-01-13 2020-05-12 天津民祥生物医药股份有限公司 一种维格列汀的制备方法
JP7349475B2 (ja) * 2021-06-22 2023-09-22 シャープ株式会社 リレー制御回路および電源回路
US20250353833A1 (en) * 2022-06-03 2025-11-20 Universiteit Antwerpen Dpp9 binding compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5150173A1 (es) * 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6555519B2 (en) * 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
US6683056B2 (en) * 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6995183B2 (en) * 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
EP1970377A4 (en) * 2005-12-09 2013-02-27 Meiji Seika Kaisha LINCOMYCIN DERIVATIVE AND ANTIBACTERIAL AGENT CONTAINING THIS AS AN ACTIVE SUBSTANCE

Also Published As

Publication number Publication date
US20100256080A1 (en) 2010-10-07
CN101918423B (zh) 2013-05-15
JP2011504903A (ja) 2011-02-17
KR20100092461A (ko) 2010-08-20
RU2489439C2 (ru) 2013-08-10
RU2010126056A (ru) 2012-01-10
AU2008328845C1 (en) 2012-11-08
US8252751B2 (en) 2012-08-28
EP2247602A2 (en) 2010-11-10
CA2704493A1 (en) 2009-06-04
RU2013119129A (ru) 2014-10-27
PL2247602T3 (pl) 2013-08-30
AU2008328845B2 (en) 2012-04-19
ES2418440T3 (es) 2013-08-13
AU2008328845A1 (en) 2009-06-04
CN101918423A (zh) 2010-12-15
EP2247602B1 (en) 2013-04-03
WO2009068531A2 (en) 2009-06-04
WO2009068531A3 (en) 2010-09-10
MX2010005914A (es) 2010-12-14
PT2247602E (pt) 2013-07-10
US20120295860A1 (en) 2012-11-22
US8569250B2 (en) 2013-10-29

Similar Documents

Publication Publication Date Title
JP5401465B2 (ja) 有機化合物
EP1638963B1 (en) N-acyl nitrogen heterocycles as ligands of peroxisome proliferator-activated receptors
KR100509311B1 (ko) Ｎ-치환된 2-시아노피롤리딘
US7538135B2 (en) Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds
WO2005073186A1 (ja) ピロリジン誘導体
CN101223164A (zh) 作为肾素抑制剂的被取代的哌啶类
CN101326180A (zh) 哌嗪衍生物肾素抑制剂
CN101466668A (zh) 作为肾素抑制剂的吡咯烷化合物
KR100792275B1 (ko) 베타아미노기를 갖는 고리화된 히드라자이드 유도체, 이의 약학적으로 허용 가능한 염 및 이의 제조 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130813

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20130816

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131008

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131028

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees